Week in Review: WuXi AppTec Acquires HD Biosciences in China CRO Tieup

WuXi AppTec, China's largest CRO/CMO, acquired Shanghai's HD Biosciences, an early stage biologics CRO; New Century Healthcare completed a $114 million IPO in Hong Kong expand its Beijing chain of children's and women's clinics/hospitals; China internet giant Tencent led a $55 million Series D funding in Practo, an Indian mobile healthcare site; Shijiazhuang Yiling Pharma invested $20 million in HealthWatch, an Israeli company with a wearable vital sign monitoring shirt; Shanghai's RMX Biopharma in-licensed China rights to a next-gen antibiotic from LegoChem of South Korea; Renhe Group of Beijing and Switzerland's Applied Pharma Research partnered to distribute a migraine treatment in greater China; the WuXi AppTec-MedImmune arthritis biologic candidate received CFDA permission to begin clinical trials; and Shanghai's CloudHealth Genomics launched HealthySeq, a whole genome next generation sequencing liquid biopsy aimed at healthy individuals. More details.... Stock Symbols: (HK: 0700) (SHZ: 2603) Share this with colleagues: // //